was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue.

In March 2009, Roche fully acquired Genentech and made it a wholly owned subsidiary by buying all remaining shares it did not already control for approximately $46.8 billion.

In July 2014, Genentech acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful development of products in Seragon's pipeline.

1.Previous
3.Next